Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APP _Swe /PS1ΔE9 Transgenic Female Mice.

ABSTRACT: Alzheimer's disease (AD) is a neurodegenerative disease that causes behavioral and cognitive impairments. The phytocannabinoid cannabidiol (CBD) has anti-inflammatory, antioxidant, and neuroprotective properties, and in vitro and limited in vivo evidence suggests that CBD possesses therapeutic-like properties for the treatment of AD. Cannabinoids are known to have dose-dependent effects and the therapeutic potential of medium-dose CBD for AD transgenic mice has not been assessed in great detail yet. 12-month-old control and APP _Swe /PS1ΔE9 (APPxPS1) transgenic female mice were treated daily via intraperitoneal injection with 5 mg/kg bodyweight CBD (or vehicle) commencing three weeks prior to the assessment of behavioral domains including

SUBMITTER: Coles M 

PROVIDER: S-EPMC7789874 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature